192 related articles for article (PubMed ID: 9892195)
1. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen.
Stan AC; Radu DL; Casares S; Bona CA; Brumeanu TD
Cancer Res; 1999 Jan; 59(1):115-21. PubMed ID: 9892195
[TBL] [Abstract][Full Text] [Related]
2. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
[TBL] [Abstract][Full Text] [Related]
3. Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates.
Dillman RO; Johnson DE; Ogden J; Beidler D
Mol Biother; 1989; 1(5):250-5. PubMed ID: 2515870
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
[TBL] [Abstract][Full Text] [Related]
5. Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates.
Takahashi H; Adachi K; Yamaguchi F; Teramoto A
Anticancer Res; 1999; 19(5B):4151-5. PubMed ID: 10628367
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier.
Shih LB; Goldenberg DM; Xuan H; Lu H; Sharkey RM; Hall TC
Cancer Res; 1991 Aug; 51(16):4192-8. PubMed ID: 1868440
[TBL] [Abstract][Full Text] [Related]
7. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
8. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma.
Sivam GP; Martin PJ; Reisfeld RA; Mueller BM
Cancer Res; 1995 Jun; 55(11):2352-6. PubMed ID: 7757986
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.
King HD; Yurgaitis D; Willner D; Firestone RA; Yang MB; Lasch SJ; Hellström KE; Trail PA
Bioconjug Chem; 1999; 10(2):279-88. PubMed ID: 10077478
[TBL] [Abstract][Full Text] [Related]
12. Targeted sonodynamic therapy of cancer using a photosensitizer conjugated with antibody against carcinoembryonic antigen.
Abe H; Kuroki M; Tachibana K; Li T; Awasthi A; Ueno A; Matsumoto H; Imakiire T; Yamauchi Y; Yamada H; Ariyoshi A; Kuroki M
Anticancer Res; 2002; 22(3):1575-80. PubMed ID: 12168839
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel immunoconjugate for the specific treatment of ovarian cancer in vitro.
Jaime J; Pagé M
Anticancer Res; 2001; 21(2A):1119-28. PubMed ID: 11396150
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug.
Inoh K; Muramatsu H; Torii S; Ikematsu S; Oda M; Kumai H; Sakuma S; Inui T; Kimura T; Muramatsu T
Jpn J Clin Oncol; 2006 Apr; 36(4):207-11. PubMed ID: 16611663
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of CC49-doxorubicin immunoconjugates.
Johnson DA; Briggs SL; Gutowski MC; Barton R
Anticancer Res; 1995; 15(4):1387-93. PubMed ID: 7654026
[TBL] [Abstract][Full Text] [Related]
17. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
Griffiths GL; Mattes MJ; Stein R; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Dec; 9(17):6567-71. PubMed ID: 14695162
[TBL] [Abstract][Full Text] [Related]
18. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
19. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
20. Increased effects of MPDAX, a novel xanthine derivative, on antitumor activity of doxorubicin.
Sadzuka Y; Sugiyama T; Suzuki H; Sawanishi H; Miyamoto K
Toxicol Lett; 2004 May; 150(3):341-9. PubMed ID: 15110086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
